دورية أكاديمية
Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma.
| العنوان: | Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma. |
|---|---|
| المؤلفون: | Jaremtchuk AV; GETICS (Grupo de Estudio Tratamiento e Investigación del Cáncer, del Sur). Clinica Santa Lucía, Comodoro Rivadavia, Argentina., Aman EF, Ponce W, Zarbá JJ, Ferro AM, Alvarez R, Vigo SA |
| المصدر: | American journal of clinical oncology [Am J Clin Oncol] 2002 Apr; Vol. 25 (2), pp. 123-5. |
| نوع المنشور: | Clinical Trial; Clinical Trial, Phase II; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print Cited Medium: Print ISSN: 0277-3732 (Print) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: New York, N.Y. : Masson Pub. USA, c1982- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Renal Cell/*drug therapy , Interferon-alpha/*administration & dosage , Isotretinoin/*administration & dosage , Kidney Neoplasms/*drug therapy, Adult ; Aged ; Female ; Humans ; Interferon alpha-2 ; Male ; Middle Aged ; Recombinant Proteins ; Survival Analysis |
| مستخلص: | Retinoids and interferon alpha have shown synergistic activity against metastatic renal cell carcinoma in previous preclinical and clinical studies. Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week. Thirty-one patients were entered, all evaluable for toxicity and 30 evaluable for response. One patient achieved a partial response and 10 patients achieved stable disease. Toxicity was mild and primarily related to interferon. No toxic deaths were reported. Median survival time was 10 months. At the dose and schedule used, cRA and interferon-alpha2a showed low activity against metastatic renal cell carcinoma. Further studies with this combination are not recommended. |
| المشرفين على المادة: | 0 (Interferon alpha-2) 0 (Interferon-alpha) 0 (Recombinant Proteins) EH28UP18IF (Isotretinoin) |
| تواريخ الأحداث: | Date Created: 20020411 Date Completed: 20020425 Latest Revision: 20190906 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1097/00000421-200204000-00004 |
| PMID: | 11943887 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0277-3732 |
|---|---|
| DOI: | 10.1097/00000421-200204000-00004 |